All In MedTech

Device Trial Radar · NCT07172464

Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 9, 2025

Primary completion

Aug 2027

Study completion Feb 2032

Sponsor

Lead sponsor
Recross Cardio, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
MCRA
First posted
Sep 15, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a stroke that may be related to this heart opening. The main question it aims to answer is: • Is the P3 Occluder System safe and effective for closing a PFO in patients who have had a stroke that could be related to a PFO. Participants will: * Undergo the procedure to implant the P3 Occluder System, if deemed appropriate. * Visit their doctor at 1 month, 3 months, 6 months, 1 year and 5 years after the procedure for follow up exams. * Answer a phone call from study staff at 2 years, 3 years and 4 years after the procedure to answer a survey.

Conditions

  • PFO
  • PFO - Patent Foramen Ovale
  • Cryptogenic Stroke
  • Patent Foramen Ovale
  • PFO-associated Stroke

Interventions

  • Recross P3 Occluder (P3O) SystemDevice

    The Recross P3 Occluder (P3O) is being developed for the purpose of transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety Endpoint - Rate of Major Adverse Cardiovascular Events (MACE)Time frame: 30 days
  2. Primary Performance Endpoint - Effective PFO ClosureTime frame: 6 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California · Recruiting

  • The Cardiac and Vascular Institute

    Gainsville, Florida · Recruiting

  • Tufts Medical Center

    Boston, Massachusetts · Recruiting

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.